Friday, March 4

Tysabri's withdrawal big blow to Biogen, Elan: Firms hoped to expand sales for multiple sclerosis drugs

The sudden withdrawal of the new multiple sclerosis drug Tysabri is a major blow to drug developers Biogen Idec and Elan Pharmaceuticals, both of which hoped to dramatically expand the market for such medications by as much as 30 percent.